

PTO/SB/21 (02-04)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/767,784
	Filing Date	January 29, 2004
	First Named Inventor	Galley et al.
	Art Unit	
	Examiner Name	
Total Number of Pages in This Submission	Attorney Docket Number	21453 US

ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement	<input type="checkbox"/> Request for Refund	
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Remarks	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	-References C1 to C10; and -PTO-1449 Form	
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT		
Firm or Individual name	Kimberly J. Prior	
Signature		
Date	5/4/2004	

CERTIFICATE OF TRANSMISSION/MAILING		
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.		
Typed or printed name	Kimberly J. Prior	
Signature		Date 5/4/2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application

Inventors: Galley, et al.

Serial No. 10/767,784, filed January 29, 2004
(Ref. No. 21453 US)

For: **MALONAMIDE DERIVATIVES**

INFORMATION DISCLOSURE STATEMENT

Nutley, New Jersey 07110
May 4, 2004

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Pursuant to 37 C.F.R. §§ 1.56, 1.97 and 1.98, applicants respectfully direct the Examiner's attention to the documents listed on enclosed Form PTO-1449.


Documents C1 to C10, listed on Form PTO-1449 are enclosed.

Consideration of all the documents cited on Form PTO-1449 is requested.

Serial No. 10/767,784
Filed: January 29, 2004

Since the Information Disclosure Statement is submitted before the mailing of the first Office Action on the merits or within three months of the filing date for the above application, no fee is due.

Respectfully submitted,

A handwritten signature in black ink, appearing to read "Kimberly J. Prior", is written over a horizontal line.

Attorney for Applicant(s)
Kimberly J. Prior
(Reg. No. 41,483)
340 Kingsland Street
Nutley, New Jersey 07110
Telephone: (973) 235-6208
Telefax: (973) 235-2363

Enclosures

141588

Substitute for form 1449A/PTO				Complete if Known			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Application Number	10/767,784		
				Filing Date	January 29, 2004		
				First Name Inventor	Galley, et al.		
(Use several sheets if necessary)				Attorney Docket Number	21453 US		
U.S. PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited document MM-DD-YYYY		
		Number	Kind Code ² (if known)				
	A						
FOREIGN PATENT DOCUMENTS							
Examiner Initials ¹	Cite No. ¹	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	T ⁶
		Office ³	Number ⁴	Kind Code ⁵ (if known)			
	B						

NON PATENT LITERATURE DOCUMENTS

Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	C1	Sisodia, S., et al., <i>Nature Reviews/Neuroscience</i> , Vol. 3, April, 2002, pgs. 281-290	
	C2	Wolfe, M. S., <i>Current Topics in Medicinal Chem.</i> , 2002, Vol. 2, pgs. 371-383	
	C3	Tsai, J., et al., <i>Current Medicinal Chemistry</i> , 2002, Vol. 9, No. 11, pgs. 1087-1106	
	C4	Sambamurti, K., et al., <i>Drug Development Research</i> , Vol. 56, 2002, pgs. 211-227	
	C5	May, P. C., <i>Drug Discovery Today</i> , Vol. 6, No. 9, May, 2001, pgs. 459-462	
	C6	Nunan, J. et al., <i>FEBS Letters</i> , Vol. 483, 2000, pgs. 6-10	
	C7	Hardy, J. et al., <i>Science</i> , Vol. 297, July 19, 2002, pgs. 353-356	
	C8	Wolfe, M. S., <i>Journ. Of Medicinal Chemistry</i> , Vol. 44, No. 13, 2001, pgs. 2039-2060	
	C9	Li, Y. et al., <i>PNAS</i> , Vol. 97(11), 2000, pgs. 6138-6143	
	C10	Brockhaus, M. et al., <i>Neuro Report</i> , Vol. 9(7), 1998, pgs. 1481-1486	
Examiner Signature		Date Considered	

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Unique citation designation number. ³See attached Kinds of U.S. Patent Documents. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation or abstract is attached.

141589